Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition Mohammad Mehdi AmiriForough Golsaz-ShiraziFazel Shokri PRECLINICAL STUDIES 06 October 2017 Pages: 171 - 186
Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer Lei FangHao WangPeiling Li PRECLINICAL STUDIES 30 October 2017 Pages: 187 - 194
Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer Sang Eun ParkHa-Gyeong KimChoung-Soo Kim PRECLINICAL STUDIES 07 November 2017 Pages: 195 - 205
Antitumor activity of raloxifene-targeted poly(styrene maleic acid)-poly (amide-ether-ester-imide) co-polymeric nanomicelles loaded with docetaxel in breast cancer-bearing mice Saeede EnteshariJaleh VarshosazFarshid Hassanzadeh PRECLINICAL STUDIES 27 November 2017 Pages: 206 - 216
4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma Arpita DeBlake A. JacobsonRobert A. Kratzke PRECLINICAL STUDIES 08 November 2017 Pages: 217 - 229
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile Giovanna SperanzaLarry AndersonShivaani Kummar PHASE I STUDIES 12 August 2017 Pages: 230 - 239
Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies Xiaofei ZhouJohn NemunaitisKarthik Venkatakrishnan PHASE I STUDIES Open access 18 August 2017 Pages: 240 - 247
Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies Xiaofei ZhouShubham PantKarthik Venkatakrishnan PHASE I STUDIES Open access 30 August 2017 Pages: 248 - 258
Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study Yutaka FujiwaraNaoya YamazakiTomohide Tamura PHASE I STUDIES 07 September 2017 Pages: 259 - 268
Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies Meiqi ShiJing SunYaling Shen PHASE I STUDIES 04 September 2017 Pages: 269 - 277
A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer Evan Y. YuSusan L. EllardKim N. Chi PHASE II STUDIES 18 December 2017 Pages: 278 - 287
A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer Muhammad AlamgeerD. Neil WatkinsVinod Ganju PHASE II STUDIES 26 December 2017 Pages: 288 - 298
A phase II study of tipifarnib and gemcitabine in metastatic breast cancer Clinton YamRashmi K. MurthyBanu Arun PHASE II STUDIES 27 January 2018 Pages: 299 - 306
The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis Yuan-Hung KuoI-Pei WuSheng-Nan Lu PHASE III STUDIES 02 May 2017 Pages: 307 - 314
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer Xuenong OuyangMeiqi ShiJifeng Feng PHASE III STUDIES 14 November 2017 Pages: 315 - 322
Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas Franciele Cristina KipperAndrew Oliveira SilvaGuido Lenz SHORT REPORT 29 August 2017 Pages: 323 - 331
Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment Sadahisa OgasawaraTetsuhiro ChibaNaoya Kato SHORT REPORT 11 September 2017 Pages: 332 - 339
Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy Francesco PasqualettiAlessandra GonnelliFabiola Paiar SHORT REPORT 30 September 2017 Pages: 340 - 345
Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature Shoichi DeguchiKoichi MitsuyaMasahiro Endo SHORT REPORT Open access 25 October 2017 Pages: 346 - 349
Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer Emi DateKunio OkamotoHiroyasu Kaneda SHORT REPORT 11 October 2017 Pages: 350 - 353